Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite
| Autor: | Serena Buttafava, Giorgio Ciprandi, Piercarlo Poli, Salvatore Barberi, Enza D'Auria, Franco Frati, Cristoforo Incorvaia, Enrica Riva, Benedetta Pietra, Elvira Verduci |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Allergen immunotherapy
Allergy Dermatology medicine.disease_cause Allergic inflammation Allergen immune system diseases medicine Immunology and Allergy Child Respiratory Tract Infections Sensitization House dust mite Mites Sublingual Immunotherapy Respiratory tract infections biology business.industry respiratory system Eosinophil Allergens biology.organism_classification medicine.disease respiratory tract diseases medicine.anatomical_structure Immunology Original Article business |
| Zdroj: | Asia Pacific Allergy |
| ISSN: | 2233-8276 |
| Popis: | Background Allergic rhinitis is characterized by eosinophil inflammation. Allergic inflammation may induce susceptibility to respiratory infections (RI). House dust mite (HDM) sensitization is very frequent in childhood. Allergen immunotherapy may cure allergy as it restores a physiologic immune and clinical tolerance to allergen and exerts anti-inflammatory activity. Objective This study investigated whether six-month high-dose, such as 300 IR (index of reactivity), HDM-sublingual immunotherapy (SLIT) could affect RI in allergic children. Methods Globally, 40 HDM allergic children (18 males; mean age, 9.3 years) were subdivided in 2 groups: 20 treated by symptomatic drugs (group 1) and 20 by high-dose HDM-SLIT (group 2), since September 2012 to April 2013. The daily maintenance dose of HDM-SLIT was 4 pressures corresponding to 24, 4.8, and 60 µg, respectively of the major allergens Dermatophagoides pteronyssinus (Der p) 1, Der p 2, and Dermatophagoides farinae (Der f) 1. RI was diagnosed when at least 2 symptoms or signs, and fever were present for at least 48 hours. A family pediatrician provided diagnosis on a clinical ground. Results SLIT-treated children had significantly (p = 0.01) less RI episodes (3.5) than control group (5.45). About secondary outcomes, SLIT-treated children had less episodes of pharyngo-tonsillitis (p < 0.05) and bronchitis (p < 0.005), and snoring (p < 0.05) than control group. In addition, SLIT-treated children had less fever (p < 0.01) and took fewer medications, such as antibiotics (p < 0.05) and fever-reducers (p < 0.01), than control group. Conclusion This preliminary study might suggest that also a short course (6 months) of high-dose SLIT, titrated in µg of major allergens, could reduce RI in allergic children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|